stockrow
Friday 6 November 2026
Export OCS’s income statement to Excel — free account
Oculis Holding AG
Oculis Holding AG’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 85.7% from fiscal 2024.
- Revenue
- −97.2%
- EPS
- +9.20%
- Free cash flow
- −20.9%
- Total debt
- −4.44%
Quarter to September 2026, against a year earlier
7.49
0.66
+9.66%
Follow OCS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 1 | 1 | 1 | 1 | 1 | 1 | +8.3% | 1 | 5 | 51 | +228.7% | |
| Gross margin, % | — | — | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 0.0 pt | ||||||
| EBT | — | — | — | — | — | (20) | (40) | (99) | (98) | (120) | (103) | +55.9% | ||||||
| EBT margin, % | — | — | — | — | — | (1,929.65) | (4,237.10) | (10,044.47) | (12,527.70) | (8,268.77) | (8,742.43) | (6,339.1) pt | ||||||
| Net income | — | — | — | — | — | (20) | (40) | (99) | (98) | (120) | (96) | +55.9% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.38 | 0.32 | 0.03 | 0.02 | 0.03 | 0.02 | (48.0%) | |||||
| Earnings | — | — | — | — | — | (7.31) | (13.57) | (3.31) | (2.41) | (2.28) | (1.74) | (25.3%) | ||||||
| Cash flow | — | — | — | — | — | (5.44) | (8.79) | (2.01) | (1.34) | (1.53) | (1.38) | (27.2%) | ||||||
| Capex | — | — | — | — | — | (0.01) | (1.24) | 0.00 | (0.01) | (0.03) | 0.00 | +30.7% | ||||||
| Free cash flow | — | — | — | — | — | (5.46) | (10.03) | (2.01) | (1.34) | (1.56) | (1.38) | (26.8%) | ||||||
| Book value | — | — | — | — | — | (24.01) | (34.35) | 3.49 | 2.06 | 4.53 | 4.16 | n/m | ||||||
| Shares, m | — | — | — | — | — | 3 | 3 | 30 | 40 | 52 | 59 | +108.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 107.67 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.5 | |||||
| P/S | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 881.46 | 720.95 | 393.17 | 320.5 | ||||||
| P/B | — | — | — | — | — | 0.00 | 0.00 | 3.36 | 8.24 | 4.41 | 1.80 | 3.2 | ||||||
| EV/Sales | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 739.37 | 545.04 | 175.67 | 256.9 | ||||||
| EV/FCF | — | — | — | — | — | (14.97) | (2.80) | (3.63) | (10.62) | (9.65) | (2.39) | (8.3) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (15) | (26) | (60) | (54) | (80) | (85) | +51.7% | |||||
| Capex | — | — | — | — | — | 0 | (4) | 0 | 0 | (2) | 0 | +172.0% | ||||||
| Free cash flow | — | — | — | — | — | (15) | (30) | (60) | (54) | (82) | (85) | +52.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 48 | 12 | 91 | 69 | 220 | 239 | +46.3% | |||||
| Net debt | — | — | — | — | — | 74 | 108 | (101) | (111) | (255) | (256) | n/m | ||||||
| Shareholders’ equity | — | — | — | — | — | (67) | (103) | 104 | 83 | 237 | 257 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | (79.25) | (119.02) | (73.79) | (56.67) | (41.38) | (56.7) pt | |||||
| ROIC | — | — | — | — | — | (120.78) | (391.93) | (1,747.97) | 0.00 | 0.00 | (12,858.67) | +120.8 pt | ||||||
| ROE | — | — | — | — | — | 0.00 | 47.88 | (11,509.96) | (103.79) | (74.65) | (48.81) | (74.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 32 | 28 | 36 | 49 | 60 | — | +17.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | — | (7.4%) | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026
Oculis Holding AG vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| EPRX Eupraxia Pharmaceuticals Inc. | $429.1M | — (loss-making) | — | — | n/m | −56.41% (below 0%: shrinking) | — | 0.00% | Compare |
| ARVN Arvinas, Inc. | $428.9M | — (loss-making) | — (loss-making) | −98.81% (below 0%: shrinking) | n/m | +82.77% (above 0%: growing) | 80.00% | (11,820.00%) | Compare |
| GYRE Gyre Therapeutics, Inc. | $425.2M | — (loss-making) | — (loss-making) | +7.75% (above 0%: growing) | n/m | −129.91% (below 0%: shrinking) | 94.09% | 0.00% | Compare |
| PRTCY PureTech Health PLC Sponsored ADR | $424.0M | — (loss-making) | — (loss-making) | −44.60% (below 0%: shrinking) | +66.43% (above 0%: growing) | +19.27% (above 0%: growing) | 2.83% | 0.00% | Compare |
| OCS Oculis Holding AG | $421.6M | — (loss-making) | — (loss-making) | −97.17% (below 0%: shrinking) | n/m | −20.85% (below 0%: shrinking) | 100.00% | (338,436.05%) | |
| PHAT Phathom Pharmaceuticals, Inc. | $413.0M | — (loss-making) | — (loss-making) | +71.14% (above 0%: growing) | n/m | +112.23% (above 0%: growing) | 78.32% | (0.10%) | Compare |
| CRMD CorMedix Inc | $407.6M | 2.2× | 11.5× | +156.52% (above 0%: growing) | +13.79% (above 0%: growing) | +185.90% (above 0%: growing) | 75.66% | 42.10% | Compare |
| ASMB Assembly Biosciences, Inc. | $407.2M | — (loss-making) | — (loss-making) | +38.94% (above 0%: growing) | n/m | +7.58% (above 0%: growing) | 100.00% | (47.44%) | Compare |
| PRTA Prothena Corporation plc | $405.1M | — (loss-making) | 71.4× | −74.33% (below 0%: shrinking) | n/m | +70.34% (above 0%: growing) | 100.00% | (3,035.65%) | Compare |
| Median of peers | $418.5M | — | — | +7.75% | — | +44.81% | 80.00% | (0.05%) |